The Massachusetts Life Sciences Center (MLSC), Massachusetts General Hospital (MGH) and five leading biopharma companies have launched the Massachusetts Center for Alzheimer Therapeutics Science (MassCATS), a unique collaboration among world-class industry and academic researchers working to find therapies for Alzheimer’s disease. The new Center will be located at MGH. Industry partners, including AbbVie, Biogen, Janssen Pharmaceuticals, Inc., Merck and Sunovion Pharmaceuticals have committed $1.25 million in Alzheimer’s-related research funding.
Read the press release here
(left to right). Massachusetts Assistant Secretary for Economic Development Mike Kennealy, Alzheimer’s advocate and caregiver Brenda Bouchard, Massachusetts Secretary for Housing & Economic Development Jay Ash, Director of MA Alzheimer’s Disease Research Center Brad Hyman, Ph.D., Massachusetts General Hospital President & CEO Peter Slavin, Massachusetts Life Sciences Center General Counsel and VP for Academic & Workforce Programs Beth Nicklas, and Massachusetts Life Sciences Center President & CEO Travis McCready celebrate the launch of the new Massachusetts Center for Alzheimer Therapeutics Science (MassCATS) at Massachusetts General Hospital.